Prior to the identification of antibodies against aquaporin-4 (AQP4) being specific for NMO spectrum disorders3, distinguishing MS from NMO was mainly based on clinical decision-making4, and NMO specific treatment algorithms were not available. This evidence concerns the gene AQP4 and neuromyelitis optica.